• Explore /
  • Poster
  • / KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.

KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.

Abstract Poster

Authors

Saad Usmani

Saad Z. Usmani

Levine Cancer Institute, Charlotte, NC

Saad Z. Usmani , Jesus G. Berdeja , Anna Truppel-Hartmann , Yizhou Fei , Honeylet Wortman-Vayn , Suresh Shelat , Steven Novick , Nina Shah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT04196491

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS8053)

DOI

10.1200/JCO.2021.39.15_suppl.TPS8053

Abstract #

TPS8053

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: E. Bridget Kim

First Author: Robert M. Rifkin

First Author: Cristina Gasparetto

First Author: Larry D. Anderson, Jr